Sodium Lactate — Active Pharmaceutical Ingredient

Sodium Lactate is an active pharmaceutical ingredient found in 65 FDA-approved drug products. Forms: SOLUTION, INJECTABLE. Routes: INTRAPERITONEAL, INJECTION, IRRIGATION.

Drug Ingredients A–Z 5 min read
This content is for informational purposes only. Always consult a healthcare professional.

Sodium Lactate (65 brand names, 2 dosage forms, 3 routes)

Available dosage forms: SOLUTION, INJECTABLE.

Routes of administration: INTRAPERITONEAL, INJECTION, IRRIGATION.

Brand Names

  • DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER
  • DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
  • DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
  • DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
  • DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
  • DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
  • DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER’S IN PLASTIC CONTAINER
  • DEXTROSE 4% IN MODIFIED LACTATED RINGER’S IN PLASTIC CONTAINER
  • DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER
  • DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER
  • DEXTROSE 5% AND LACTATED RINGER’S
  • DEXTROSE 5% AND LACTATED RINGER’S IN PLASTIC CONTAINER …and 45 more

Indications and Usage

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent.

Dosage and Administration

Important Administration Instructions •5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is intended for intravenous administration using sterile equipment. •Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. •Set the vent to the closed position on a vented intravenous administration set to prevent air embolism. •Use a dedicated line without any connections to avoid air embolism. •Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container. •Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged. •Do not administer 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis. Dosing Information The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy. Introduction of Additives Additives may be incompatible. Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do

Contraindications

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is contraindicated in patients •with a known hypersensitivity to the product (see WARNINGS ) •with clinically significant hyperglycemia (see WARNINGS)

Drug Interactions

Other Products that Affect Fluid and/or Electrolyte Balance Administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) to patients treated concomitantly with drugs associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload. Avoid use of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients receiving such products, such as corticosteroids or corticotropin. If use cannot be avoided, monitor serum electrolytes, fluid balance and acid-base balance. Other Drugs that Increase the Risk of Hyponatremia Administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients treated concomitantly with medications associated with hyponatremia may increase the risk of developing hyponatremia. Avoid use of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids. If use cannot be avoided, monitor serum sodium concentrations. Other Products that Increase the Risk of Hyperkalemia Because of its potassium content, avoid use of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients receiving products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine. If use cannot be avoided, monitor serum potassium concentrations. Lithium Renal clearance of lithium may be increased during administration of 5% Dextrose and E

Overdosage

Excessive administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause: •fluid overload with a risk of edema (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired. •hyperglycemia, hyperosmolarity, and osmotic diuresis, dehydration and electrolyte loss. •hypernatremia and hyperkalemia, especially in patients with severe renal impairment. •hypermagnesemia. •metabolic alkalosis with or without hypokalemia and decreased ionized serum calcium and magnesium concentrations. •Hyperphosphatemia, hypocalcemia, and hypomagnesemia. See WARNINGS When assessing an overdose, any additives in the solution must also be considered. The effects of an overdose may require immediate medical attention and treatment. Interventions include discontinuation of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP), dose reduction, and other measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid base balance).

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.